Navidea Envisions a World Where Disease can be Precisely Identified and Treated

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a leader in precision medicine with immuno-targeted products designed to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care.

Applying our Manocept™ technology, Navidea seeks to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases.

Learn More

The Sale of Lymphoseek® to Cardinal Health

Navidea Biopharmaceuticals has sold the North American rights of its Lymphoseek® product to Cardinal Health. Lymphoseek® is used for lymphatic mapping, lymph node biopsy and the diagnosis of metastatic spread to lymph nodes for the staging of cancer.

Read Press Release

Latest Event

Nov 10, 2021 • 5:00pm EST

Q3 2021 Earnings Conference Call

View All Events

Navidea Biopharmaceuticals, Inc.


NYSE American: NAVB




Day Range

Year Range